Azithromycin Mass Treatment Reduces Childhood Mortality, but May Not Stop Resistance Spread

1 min read

In a significant breakthrough, researchers have investigated the potential for antimicrobial resistance to spread from mass distribution of azithromycin. To address this concern, Srivathsan A et al. conducted large-scale trials in high-mortality settings in sub-Saharan Africa. These studies demonstrated a 14-18% reduction in childhood mortality following twice-annual mass drug administration (MDA) of azithromycin among children aged 1-59 months.

However, the same MDA also selected for antimicrobial resistance (AMR), particularly macrolide resistance. A crucial question remained: whether this AMR from azithromycin MDA could spill over to neighboring untreated populations. To examine this possibility, researchers used metagenomic deep sequencing in rectal swabs collected from children in 30 monitoring villages in Niger. They assessed between-village geographic spillover effects of genotypic macrolide resistance.

The findings were striking: no evidence of geographic spillover of macrolide resistance was detected. The genetic load of AMR remained at baseline levels in placebo-treated villages, regardless of surrounding azithromycin treatment intensity. This suggests that the introduction of azithromycin into a community does not lead to an increased risk of macrolide resistance in untreated areas.

This research has important implications for public health policy. By understanding the potential for antimicrobial resistance to spread, policymakers can make more informed decisions about mass drug administration programs and other interventions aimed at reducing mortality rates. As we consider these strategies, it is worth reflecting on our place within the larger ecosystem of disease and resistance – a complex web of interactions that underscores the intricate balance between human health and the natural world.

1 min read

In a small village in Niger, a child's life is marked by the rhythm of seasons, the call of birds, and the gentle touch of a caregiver's hand. But in this corner of Africa, where mortality rates are high and resources scarce, the threat of disease looms large. That's why the villagers have been given a lifeline: twice-a-year doses of azithromycin, an antibiotic that has already shown promise in saving lives.

For two years, 594 villages received these mass drug administrations, with some children as young as one month old and others up to 59 years old. And it worked – or at least, so the results suggest: a reduction in childhood mortality of 14-18%. But what happens when this lifesaving medicine is stopped? Does its effect persist, even if no more doses are given? The researchers wanted to know.

They took swabs from 300 children in 30 villages and analyzed them for signs of antibiotic resistance. To their surprise, the genetic load of antimicrobial resistance remained at baseline levels – even in the untreated villages nearby. This means that there's no evidence of "spillover" or the spread of resistant bacteria to unaffected populations. It's a reassuring finding, but also one that underscores the importance of continued vigilance and responsible use of antibiotics like azithromycin.

1 min read

In a small village in Niger, a team of researchers studied the impact of giving children an antibiotic called azithromycin twice a year to keep them healthy. They found that it helped reduce child deaths by 14-18%. But they wondered if this treatment might be making bacteria more resistant to the antibiotic.

To find out, the researchers took swabs from 300 children in their village and compared them to children in other villages nearby. What they discovered was surprising: the treatment didn't make the bacteria in those other villages any more resistant to azithromycin. It's as if the two groups of bacteria were separate and unaffected by each other, even though the two villages were close together. This discovery is important because it helps us understand how antibiotic treatments can affect bacteria in different places.